Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GH Research PLC GHRS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • IE • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$36.50
+114.7%

GH Research PLC (GHRS) is a Biotechnology company in the Healthcare sector, currently trading at $17.00. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is GHRS = $37 (+114.7% upside).

Valuation: GHRS trades at a trailing Price-to-Earnings (P/E) of -18.9 (S&P 500 average ~25).

Net income is $48M (loss), growing at -144%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $512,000 against $280M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 34.13 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $288M.

Analyst outlook: 8 / 8 analysts rate GHRS as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 69/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$36.50
▲ 114.71% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for GH Research PLC, the average price target is $36.50, with a high forecast of $40.00, and a low forecast of $32.00.
Highest Price Target
$40.00
Average Price Target
$36.50
Lowest Price Target
$32.00

GHRS SharesGrow Score Overview

58/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 69/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GHRS

✓
VALUE Pass
69/100
GHRS trades at a trailing Price-to-Earnings (P/E) of -18.9 (S&P 500 average ~25). Forward PEG -0.77 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.33. Analyst consensus target is $37, implying +117.6% from the current price $17. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GHRS: +0%/yr revenue is, -144%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet GHRS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 34.13 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
GHRS: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 8 / 8 analysts rate GHRS as buy (100%). Analyst consensus target is $37 (+117.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.98-19.51
Volume69.53K
Avg Volume (30D)198.69K
Market Cap$1.05B
Beta (1Y)1.00
Share Statistics
EPS (TTM)-0.79
Shares Outstanding$61.04M
IPO Date2021-06-25
Employees50
CEOVelichka Valcheva
Financial Highlights & Ratios
Gross Profit$-335K
EBITDA$-60.34M
Net Income$-48.26M
Operating Income$-60.68M
Total Cash$280.71M
Total Debt$512K
Net Debt$-245.74M
Total Assets$288.23M
Price / Earnings (P/E)-21.5
Analyst Forecast
1Y Price Target$37.00
Target High$40.00
Target Low$32.00
Upside+117.6%
Rating ConsensusBuy
Analysts Covering8
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryIE
ExchangeNASDAQ Global Market
CurrencyUSD
ISINIE000GID8VI0

Price Chart

Track all markets on TradingView
GHRS
GH Research PLC ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
7.98 52WK RANGE 19.51

People Also View

GPCR
GPCR
Structure Therapeutics Inc.
$54.25
+1.94%
 RLAY
RLAY
Relay Therapeutics, Inc.
$15.49
+5.02%
 RCUS
RCUS
Arcus Biosciences, Inc.
$23.70
+3.00%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.54
-0.89%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 PHVS
PHVS
Pharvaris N.V.
$29.14
+1.60%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 JANX
JANX
Janux Therapeutics, Inc.
$15.04
-1.31%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message